Stock

HCW Biologics Inc.

000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol HCWB:xnas
Currency USD
united-states
NASDAQ
Open Closed
15 minutes delayed
Data provided by Cboe Global Markets
This information is not currently available for this instrument. Refresh the page or try again later.
Instrument Card
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.

Chart

This information is not currently available for this instrument. Refresh the page or try again later.
Open account to access more charting and analysis tools

Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.

Quotes

  • Bid
  • Ask
  • Open
  • Previous close
  • Volume
  • Relative volume
  • High
  • Low
This information is not currently available for this instrument. Refresh the page or try again later.

Returns

Year to date (YTD) -70.39%
1 year -96.84%
3 years -99.49%
Data provided by FactSet Research Systems

Key stats

Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -11.79
Volatility (30 days) 275.59%
Data provided by FactSet Research Systems

ESG risk

ESG risk score -
Environmental score -
Social score -
Governance score -
ESG risk category -
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+

ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).

Download ESG risk methodology (PDF)
Data provided by Morningstar / Sustain Analytics

Financials

Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX

About HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Sector Healthcare
Industry -
Market cap 0.002210132bn
Data provided by Morningstar / FactSet Research Systems

Frequently asked questions

To buy HCW Biologics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for HCW Biologics Inc. by name or ticker, choose the number of shares, and place your order.

Learn about Saxo accounts.

The ticker symbol for HCW Biologics Inc. is HCWB:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.

HCW Biologics Inc. has its primary listing on NASDAQ. You can trade HCW Biologics Inc. with a Saxo account, alongside thousands of other stocks worldwide.

Yes, HCW Biologics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include HCW Biologics Inc. as part of a broader investment portfolio.

Explore our SaxoInvestor platform.

Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like HCW Biologics Inc. or others.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992